| Heather Leigh Tattersall, MS, OTR/L | |
|
3800 Reservoir Rd Nw, Washington, DC 20007-2113 | |
| (202) 444-2000 | |
| Not Available |
| Full Name | Heather Leigh Tattersall |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 3800 Reservoir Rd Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366876815 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Heather Leigh Tattersall, MS, OTR/L 2401 Calvert St Nw, Apartment 520, Washington, DC 20008-2646 Ph: (302) 593-9424 | Heather Leigh Tattersall, MS, OTR/L 3800 Reservoir Rd Nw, Washington, DC 20007-2113 Ph: (202) 444-2000 |
News Archive
NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).
Women drinking and eating moderate amounts of caffeine during pregnancy should be reassured that they are not harming their child's intelligence, according to a study from The Research Institute at Nationwide Children's Hospital that was published in the American Journal of Epidemiology.
Mothers with many negative thoughts and feelings are more likely to give their children unhealthy food.
Cornell biomedical engineers have developed specialized white blood cells - dubbed "super natural killer cells" - that seek out cancer cells in lymph nodes with only one purpose: destroy them.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
› Verified 3 days ago
Miss Samora Casimir, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6900 Georgia Ave Nw, Washington, DC 20307 Phone: 443-802-7824 | |
Petra Doyle, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 201 8th St Ne, Suite 301, Washington, DC 20002 Phone: 202-544-5439 | |
Lisa George, MS OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4400 Jenifer St Nw, Suite 280, Washington, DC 20015 Phone: 202-244-8089 | |
Andrea L. Meehan, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 50 Irving St Nw, Washington, DC 20422 Phone: 202-745-8000 | |
Samantha Fulp, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 101 T St Ne, Washington, DC 20002 Phone: 956-278-0770 | |
Tsegie Kassahun, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1818 Newton St Nw, Washington, DC 20010 Phone: 202-328-7400 | |
Dr. Nikia Brocks, OTD,OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2411 32nd St Se, Washington, DC 20020 Phone: 202-575-5404 Fax: 301-576-5404 |